Determination of first in human dose of the T cell-redirecting bispecific antibody CT-95 targeting mesothelin and CD3

Publications
Written by Martin Lehr
Martin Lehr
Previous

A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurrent Ovarian Cancer and Other Advanced Solid Tumors
Next

Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6